TQB2922

TQB2922 is a bispecific antibody developed by Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical. Its targets are EGFR and MET (the sponsor names EGFR x c-Met). The sponsor states: TQB2922 is an anti-EGFR/c-Met bispecific IgG1 antibody that blocks EGFR and c-Met signalling by binding both receptors on tumour cells and engages antibody-dependent cellular cytotoxicity and phagocytosis via NK cells and macrophages. ClinicalTrials.gov describes the intervention as: TQB2922 is an anti-EGFR/c-Met bispecific antibody, subtype Immunoglobulin G1 (IgG1). TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus preventing tumour grow. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in colorectal cancer. The largest, NCT07044908, plans to enrol 72 participants with primary completion expected 2026-07. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.